dromlakhani Avoid kisspeptin and leptin for treating infertility in FHA
STEP 1 — Gather Information
Confirm diagnosis of FHA (exclusion of organic causes, history of stress/weight loss/exercise, amenorrhea ≥3 months or cycle >45 days), assess fertility desire, ensure a complete fertility workup has been performed, and review current medications or prior experimental therapies.
STEP 2 — Rule In / Rule Out
If the patient has FHA and is seeking infertility treatment → proceed; if FHA is absent or pregnancy is not desired → skill not applicable.
STEP 3 — Classify or Stratify
Determine whether the patient is enrolled in a research protocol or closely monitored trial investigating kisspeptin or leptin; if yes → consider use under protocol; if no → classify as outside investigational setting.
STEP 4 — Decide
If outside a research/trial setting, advise against prescribing kisspeptin or leptin for infertility; instead, recommend first-line options per guideline (pulsatile GnRH if available, gonadotropins, or clomiphene citrate if adequate estrogen level) and emphasize behavioral/nutritional rehabilitation.
Clinical Guardrails / Mimics / Pitfalls
Do not use kisspeptin or leptin outside of research due to insufficient efficacy data; avoid substituting these agents for proven therapies; monitor for potential side effects and ensure patient understands experimental nature; do not rely on kisspeptin/leptin as a shortcut for weight gain or stress reduction.
Concrete Clinical Example
A 28‑year‑old woman with FHA secondary to low body weight and stress desires pregnancy; after confirming FHA and completing a fertility workup, the clinician considers kisspeptin but, noting no trial enrollment, advises against its use, recommends weight gain, CBT, and, if GnRH unavailable, a trial of gonadotropins with careful monitoring.
Source: Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-00131